Literature DB >> 24960626

Ligand efficiency based approach for efficient virtual screening of compound libraries.

Yi-Yu Ke1, Mohane Selvaraj Coumar2, Hui-Yi Shiao3, Wen-Chieh Wang3, Chieh-Wen Chen3, Jen-Shin Song3, Chun-Hwa Chen3, Wen-Hsing Lin3, Szu-Huei Wu3, John T A Hsu3, Chung-Ming Chang3, Hsing-Pang Hsieh4.   

Abstract

Here we report for the first time the use of fit quality (FQ), a ligand efficiency (LE) based measure for virtual screening (VS) of compound libraries. The LE based VS protocol was used to screen an in-house database of 125,000 compounds to identify aurora kinase A inhibitors. First, 20 known aurora kinase inhibitors were docked to aurora kinase A crystal structure (PDB ID: 2W1C); and the conformations of docked ligand were used to create a pharmacophore (PH) model. The PH model was used to screen the database compounds, and rank (PH rank) them based on the predicted IC50 values. Next, LE_Scale, a weight-dependant LE function, was derived from 294 known aurora kinase inhibitors. Using the fit quality (FQ = LE/LE_Scale) score derived from the LE_Scale function, the database compounds were reranked (PH_FQ rank) and the top 151 (0.12% of database) compounds were assessed for aurora kinase A inhibition biochemically. This VS protocol led to the identification of 7 novel hits, with compound 5 showing aurora kinase A IC50 = 1.29 μM. Furthermore, testing of 5 against a panel of 31 kinase reveals that it is selective toward aurora kinase A &amp; B, with <50% inhibition for other kinases at 10 μM concentrations and is a suitable candidate for further development. Incorporation of FQ score in the VS protocol not only helped identify a novel aurora kinase inhibitor, 5, but also increased the hit rate of the VS protocol by improving the enrichment factor (EF) for FQ based screening (EF = 828), compared to PH based screening (EF = 237) alone. The LE based VS protocol disclosed here could be applied to other targets for hit identification in an efficient manner.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aurora kinase inhibitor; Fit quality; Ligand efficiency; Pharmacophore model; Virtual screening

Mesh:

Substances:

Year:  2014        PMID: 24960626     DOI: 10.1016/j.ejmech.2014.06.029

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity.

Authors:  Sailu Sarvagalla; Vivek Kumar Singh; Yi-Yu Ke; Hui-Yi Shiao; Wen-Hsing Lin; Hsing-Pang Hsieh; John T A Hsu; Mohane Selvaraj Coumar
Journal:  J Comput Aided Mol Des       Date:  2014-10-26       Impact factor: 3.686

2.  Efficient Hit-to-Lead Searching of Kinase Inhibitor Chemical Space via Computational Fragment Merging.

Authors:  Grigorii V Andrianov; Wern Juin Gabriel Ong; Ilya Serebriiskii; John Karanicolas
Journal:  J Chem Inf Model       Date:  2021-11-11       Impact factor: 4.956

3.  Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery.

Authors:  Lun K Tsou; Shiu-Hwa Yeh; Shau-Hua Ueng; Chun-Ping Chang; Jen-Shin Song; Mine-Hsine Wu; Hsiao-Fu Chang; Sheng-Ren Chen; Chuan Shih; Chiung-Tong Chen; Yi-Yu Ke
Journal:  Sci Rep       Date:  2020-10-08       Impact factor: 4.379

Review 4.  Computational Methods in Cooperation with Experimental Approaches to Design Protein Tyrosine Phosphatase 1B Inhibitors in Type 2 Diabetes Drug Design: A Review of the Achievements of This Century.

Authors:  Mara Ibeth Campos-Almazán; Alicia Hernández-Campos; Rafael Castillo; Erick Sierra-Campos; Mónica Valdez-Solana; Claudia Avitia-Domínguez; Alfredo Téllez-Valencia
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-14

5.  A Molecular Modeling Approach to Identify Potential Antileishmanial Compounds Against the Cell Division Cycle (cdc)-2-Related Kinase 12 (CRK12) Receptor of Leishmania donovani.

Authors:  Emmanuel Broni; Samuel K Kwofie; Seth O Asiedu; Whelton A Miller; Michael D Wilson
Journal:  Biomolecules       Date:  2021-03-18

6.  Computational Study on Potential Novel Anti-Ebola Virus Protein VP35 Natural Compounds.

Authors:  Louis K S Darko; Emmanuel Broni; Dominic S Y Amuzu; Michael D Wilson; Christian S Parry; Samuel K Kwofie
Journal:  Biomedicines       Date:  2021-11-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.